Identification

Name
Salbutamol
Accession Number
DB01001  (APRD00553)
Type
Small Molecule
Groups
Approved, Vet approved
Description

Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.

Structure
Thumb
Synonyms
  • Albuterol
Product Ingredients
IngredientUNIICASInChI Key
Salbutamol sulfate021SEF373151022-70-9BNPSSFBOAGDEEL-UHFFFAOYSA-N
Salbutamol tartrateADS4I3E22M661464-94-4VNVNZKCCDVFGAP-FPDJQMMJSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AiromirAerosol, metered100 mcgRespiratory (inhalation)Valeant Canada Lp Valeant Canada S.E.C.1998-08-13Not applicableCanada
Asmavent Nebules P.F.Liquid2.5 mgRespiratory (inhalation)Technilab Pharma Inc.1997-06-272001-09-05Canada
Asmavent Respirator Solution Inh 5mg/mlSolution5 mgRespiratory (inhalation)Technilab Pharma Inc.1993-12-312005-08-05Canada
Baca RespiclickPowder97 mcgRespiratory (inhalation)TevaNot applicableNot applicableCanada
Bci Salbutamol Inhalation SolutionSolution1 mgRespiratory (inhalation)Baker Cummins Inc2005-07-042006-10-03Canada
Bci Salbutamol Inhalation SolutionSolution2 mgRespiratory (inhalation)Baker Cummins IncNot applicableNot applicableCanada
Levalbuterol HydrochlorideSolution1.25 mg/3mLRespiratory (inhalation)Watson Pharmaceuticals2012-08-202015-12-29Us
Levalbuterol HydrochlorideSolution.63 mg/3mLRespiratory (inhalation)Watson Pharmaceuticals2012-08-202015-12-29Us
Levalbuterol HydrochlorideSolution.31 mg/3mLRespiratory (inhalation)Watson Pharmaceuticals2012-08-202015-12-29Us
Med Salbutamol Inhalation Solution 1mg/mlSolution1 mgRespiratory (inhalation)Medican Pharma Incorporated1994-12-312011-03-29Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlbuterolTablet2 mg/1OralRising Pharmaceuticals2018-06-29Not applicableUs
AlbuterolTablet2 mg/1OralAmneal Pharmaceuticals2018-05-24Not applicableUs
AlbuterolTablet4 mg/1OralMylan Institutional1997-04-29Not applicableUs
AlbuterolTablet4 mg/1OralMylan Pharmaceuticals1991-01-17Not applicableUs
AlbuterolTablet2 mg/1OralAppco Pharma Llc2018-08-01Not applicableUs
AlbuterolAerosol, metered90 ug/1OralRebel Distributors1996-08-14Not applicableUs
AlbuterolTablet2 mg/1OralMylan Institutional1997-04-29Not applicableUs
AlbuterolTablet4 mg/1OralAppco Pharma Llc2018-02-01Not applicableUs
AlbuterolTablet2 mg/1OralMylan Pharmaceuticals1991-01-17Not applicableUs
AlbuterolTablet4 mg/1OralRising Pharmaceuticals2018-06-29Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Apo-salvent-ipravent SterulesSalbutamol (2.5 mg) + Ipratropium (0.5 mg)SolutionRespiratory (inhalation)Apotex Corporation2006-08-25Not applicableCanada
Combivent Inhalation AerosolSalbutamol sulfate (120 mcg) + Ipratropium (20 mcg)Aerosol, meteredOral; Respiratory (inhalation)Boehringer Ingelheim (Canada) Ltd Ltee1995-12-312007-10-02Canada
Combivent RespimatSalbutamol (100 mcg) + Ipratropium (20 mcg)SolutionRespiratory (inhalation)Boehringer Ingelheim (Canada) Ltd Ltee2014-09-16Not applicableCanada
Combivent RespimatSalbutamol sulfate (120 ug/1) + Ipratropium (20 ug/1)Spray, meteredRespiratory (inhalation)Boehringer Ingelheim2012-07-01Not applicableUs
Combivent UdvSalbutamol (1 mg) + Ipratropium (0.2 mg)SolutionRespiratory (inhalation)Boehringer Ingelheim (Canada) Ltd Ltee1997-07-25Not applicableCanada
DuoNebSalbutamol sulfate (2.5 mg/3mL) + Ipratropium (.5 mg/3mL)SolutionRespiratory (inhalation)Mylan Specialty2011-02-152016-10-13Us
IpramolSalbutamol (2.5 mg) + Ipratropium (0.5 mg)SolutionRespiratory (inhalation)Ivax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Ipratropium Bromide and Albuterol SulfateSalbutamol sulfate (3 mg/3mL) + Ipratropium (.5 mg/3mL)SolutionRespiratory (inhalation)Mylan Pharmaceuticals2001-03-212016-10-13Us
Ipratropium Bromide and Albuterol SulfateSalbutamol sulfate (2.5 mg/3mL) + Ipratropium (.5 mg/3mL)SolutionRespiratory (inhalation)The Ritedose Corporation2012-10-15Not applicableUs
Ipratropium Bromide and Albuterol SulfateSalbutamol sulfate (2.5 mg/3mL) + Ipratropium (.5 mg/3mL)SolutionRespiratory (inhalation)Actavis Pharma Company2013-05-13Not applicableUs
International/Other Brands
AccuNeb / Aerolin / Asmol / Asthalin / Asthavent / ProAir (Teva) / PROAIRHFA / Proventil / Salamol / Ventilan (GlaxoSmithKline) / Ventolin (GlaxoSmithKline) / Ventoline (GlaxoSmithKline) / VENTOLINHFA / Ventorlin (GlaxoSmithKline) / VoSpire
Categories
UNII
QF8SVZ843E
CAS number
18559-94-9
Weight
Average: 239.3107
Monoisotopic: 239.152143543
Chemical Formula
C13H21NO3
InChI Key
NDAUXUAQIAJITI-UHFFFAOYSA-N
InChI
InChI=1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3
IUPAC Name
4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol
SMILES
CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1

Pharmacology

Indication

For symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, and other chronic bronchopulmonary disorders such as COPD.

Associated Conditions
Pharmacodynamics

Salbutamol (INN) or albuterol (USAN), a moderately selective beta(2)-receptor agonist similar in structure to terbutaline, is widely used as a bronchodilator to manage asthma and other chronic obstructive airway diseases. The R-isomer, levalbuterol, is responsible for bronchodilation while the S-isomer increases bronchial reactivity. The R-enantiomer is sold in its pure form as Levalbuterol. The manufacturer of levalbuterol, Sepracor, has implied (although not directly claimed) that the presence of only the R-enantiomer produces fewer side-effects.

Mechanism of action

Salbutamol is a beta(2)-adrenergic agonist and thus it stimulates beta(2)-adrenergic receptors. Binding of albuterol to beta(2)-receptors in the lungs results in relaxation of bronchial smooth muscles. It is believed that salbutamol increases cAMP production by activating adenylate cyclase, and the actions of salbutamol are mediated by cAMP. Increased intracellular cyclic AMP increases the activity of cAMP-dependent protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular calcium concentrations. A lowered intracellular calcium concentration leads to a smooth muscle relaxation and bronchodilation. In addition to bronchodilation, salbutamol inhibits the release of bronchoconstricting agents from mast cells, inhibits microvascular leakage, and enhances mucociliary clearance.

TargetActionsOrganism
ABeta-2 adrenergic receptor
agonist
Human
UBeta-1 adrenergic receptor
agonist
Human
UBeta-3 adrenergic receptorNot AvailableHuman
Absorption

Systemic absorption is rapid following aerosol administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hydrolyzed by esterases in tissue and blood to the active compound colterol. The drug is also conjugatively metabolized to salbutamol 4'-O-sulfate.

Route of elimination

Approximately 72% of the inhaled dose is excreted in the urine within 24 hours, 28% as unchanged drug and 44% as metabolite.

Half life

1.6 hours

Clearance
Not Available
Toxicity

LD50=1100 mg/kg (orally in mice)

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbediterolThe risk or severity of adverse effects can be increased when Abediterol is combined with Salbutamol.Investigational
AbexinostatThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Abexinostat.Investigational
AcebutololThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Acebutolol.Approved, Investigational
AcepromazineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Aceprometazine.Approved
AcrivastineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Acrivastine.Approved
AlcaftadineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Alcaftadine.Approved
AlclometasoneThe risk or severity of hypokalemia can be increased when Alclometasone is combined with Salbutamol.Approved
AldosteroneThe risk or severity of hypokalemia can be increased when Aldosterone is combined with Salbutamol.Experimental, Investigational
AlfuzosinThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Alfuzosin.Approved, Investigational
AlimemazineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Alimemazine.Approved, Vet Approved
AlprenololAlprenolol may decrease the bronchodilatory activities of Salbutamol.Approved, Withdrawn
AmantadineThe risk or severity of QTc prolongation can be increased when Amantadine is combined with Salbutamol.Approved
AmcinonideThe risk or severity of hypokalemia can be increased when Amcinonide is combined with Salbutamol.Approved
AmifampridineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Amifampridine.Approved
AmineptineThe risk or severity of hypertension can be increased when Amineptine is combined with Salbutamol.Illicit, Withdrawn
AmiodaroneThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Amiodarone.Approved, Investigational
AmitriptylineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Amitriptyline.Approved
AmitriptylinoxideThe risk or severity of hypertension can be increased when Amitriptylinoxide is combined with Salbutamol.Approved, Investigational
AmodiaquineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Amodiaquine.Approved, Investigational
AmoxapineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Amoxapine.Approved
AnagrelideThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Anagrelide.Approved
AnisodamineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Anisodamine.Investigational
AntazolineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Antazoline.Approved
ApomorphineThe risk or severity of QTc prolongation can be increased when Apomorphine is combined with Salbutamol.Approved, Investigational
ArbutamineThe risk or severity of adverse effects can be increased when Salbutamol is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Salbutamol is combined with Arformoterol.Approved, Investigational
AripiprazoleThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Aripiprazole.Approved, Investigational
Aripiprazole lauroxilThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Aripiprazole lauroxil.Approved, Investigational
ArotinololThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Arotinolol.Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Artemether.Approved
AsenapineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Asenapine.Approved
AstemizoleThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Astemizole.Approved, Withdrawn
AtazanavirThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Atazanavir.Approved, Investigational
AtenololThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Atenolol.Approved
AtomoxetineAtomoxetine may increase the tachycardic activities of Salbutamol.Approved
AtosibanThe risk or severity of adverse effects can be increased when Salbutamol is combined with Atosiban.Approved, Investigational
AzatadineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Azatadine.Approved
AzelastineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Azelastine.Approved
AzithromycinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Azithromycin.Approved
AzosemideThe risk or severity of hyperkalemia can be increased when Salbutamol is combined with Azosemide.Investigational
BambuterolThe risk or severity of adverse effects can be increased when Salbutamol is combined with Bambuterol.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of hypokalemia can be increased when Beclomethasone dipropionate is combined with Salbutamol.Approved, Investigational
BedaquilineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Bedaquiline.Approved
BefunololThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Befunolol.Experimental
BendroflumethiazideSalbutamol may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Salbutamol.Withdrawn
BenzatropineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Benzatropine.Approved
BenzthiazideSalbutamol may increase the hypokalemic activities of Benzthiazide.Approved
Benzylpenicilloyl PolylysineSalbutamol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Bepridil.Approved, Withdrawn
BesifloxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Besifloxacin.Approved
BetahistineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Betahistine.Approved, Investigational
BetamethasoneThe risk or severity of hypokalemia can be increased when Betamethasone is combined with Salbutamol.Approved, Vet Approved
BetaxololThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Betaxolol.Approved, Investigational
BevantololThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Bevantolol.Approved
BilastineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Bilastine.Approved, Investigational
BisoprololThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Bisoprolol.Approved
BitolterolThe risk or severity of adverse effects can be increased when Bitolterol is combined with Salbutamol.Withdrawn
BopindololBopindolol may decrease the bronchodilatory activities of Salbutamol.Approved
BortezomibThe risk or severity of QTc prolongation can be increased when Bortezomib is combined with Salbutamol.Approved, Investigational
BrexpiprazoleThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Brexpiprazole.Approved, Investigational
BromocriptineBromocriptine may increase the hypertensive and vasoconstricting activities of Salbutamol.Approved, Investigational
BrompheniramineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Brompheniramine.Approved
BucindololThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Bucindolol.Investigational
BuclizineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Buclizine.Approved
BudesonideThe risk or severity of hypokalemia can be increased when Budesonide is combined with Salbutamol.Approved
BufuralolThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of hyperkalemia can be increased when Salbutamol is combined with Bumetanide.Approved
BunazosinThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Bunazosin.Investigational
BupranololBupranolol may decrease the bronchodilatory activities of Salbutamol.Approved
BuserelinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Buserelin.Approved, Investigational
ButriptylineThe risk or severity of hypertension can be increased when Butriptyline is combined with Salbutamol.Approved
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Salbutamol.Approved
CarbinoxamineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Carbinoxamine.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Salbutamol.Withdrawn
CarteololCarteolol may decrease the bronchodilatory activities of Salbutamol.Approved
CarvedilolThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Carvedilol.Approved, Investigational
CeliprololThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Celiprolol.Approved, Investigational
CeritinibThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ceritinib.Approved
CetirizineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Cetirizine.Approved
ChlorcyclizineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Chlorcyclizine.Approved
ChloroquineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideSalbutamol may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Chlorphenamine.Approved
ChlorpromazineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneSalbutamol may increase the hypokalemic activities of Chlorthalidone.Approved
CiclesonideThe risk or severity of hypokalemia can be increased when Ciclesonide is combined with Salbutamol.Approved, Investigational
CilostazolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Cilostazol.Approved, Investigational
CinnarizineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Cinnarizine.Approved, Investigational
CinoxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Cisapride.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Citalopram.Approved
ClarithromycinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Clarithromycin.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Clemastine.Approved, Investigational
ClenbuterolThe risk or severity of adverse effects can be increased when Salbutamol is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClobetasolThe risk or severity of hypokalemia can be increased when Clobetasol is combined with Salbutamol.Approved, Investigational
Clobetasol propionateThe risk or severity of hypokalemia can be increased when Clobetasol propionate is combined with Salbutamol.Approved
ClobetasoneThe risk or severity of hypokalemia can be increased when Clobetasone is combined with Salbutamol.Approved
ClocortoloneThe risk or severity of hypokalemia can be increased when Clocortolone is combined with Salbutamol.Approved
ClomipramineThe risk or severity of hypertension can be increased when Clomipramine is combined with Salbutamol.Approved, Investigational, Vet Approved
CloprednolThe risk or severity of hypokalemia can be increased when Cloprednol is combined with Salbutamol.Experimental
CloranololCloranolol may decrease the bronchodilatory activities of Salbutamol.Experimental
ClozapineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Clozapine.Approved
CocaineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Cocaine.Approved, Illicit
CorticotropinThe risk or severity of hypokalemia can be increased when Corticotropin is combined with Salbutamol.Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of hypokalemia can be increased when Cortisone acetate is combined with Salbutamol.Approved, Investigational
CortivazolThe risk or severity of hypokalemia can be increased when Cortivazol is combined with Salbutamol.Investigational
CrizotinibThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Crizotinib.Approved
CUDC-101The risk or severity of QTc prolongation can be increased when Salbutamol is combined with CUDC-101.Investigational
CUDC-907The risk or severity of QTc prolongation can be increased when Salbutamol is combined with CUDC-907.Investigational
CyclizineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of hypertension can be increased when Cyclobenzaprine is combined with Salbutamol.Approved
CyclopenthiazideSalbutamol may increase the hypokalemic activities of Cyclopenthiazide.Experimental
CyproheptadineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Cyproheptadine.Approved
DabrafenibThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Dabrafenib.Approved, Investigational
DapiprazoleThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Dapiprazole.Approved
DasatinibThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Dasatinib.Approved, Investigational
DeflazacortThe risk or severity of hypokalemia can be increased when Deflazacort is combined with Salbutamol.Approved, Investigational
DegarelixThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Degarelix.Approved
DelamanidThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Delamanid.Approved, Investigational
DesfluraneThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Desflurane.Approved
DesipramineThe risk or severity of hypertension can be increased when Desipramine is combined with Salbutamol.Approved, Investigational
DesloratadineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Desloratadine.Approved, Investigational
DesonideThe risk or severity of hypokalemia can be increased when Desonide is combined with Salbutamol.Approved, Investigational
DesoximetasoneThe risk or severity of hypokalemia can be increased when Desoximetasone is combined with Salbutamol.Approved
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Salbutamol.Approved, Investigational
DeutetrabenazineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Deutetrabenazine.Approved, Investigational
DexamethasoneThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Salbutamol.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of hypokalemia can be increased when Dexamethasone isonicotinate is combined with Salbutamol.Vet Approved
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Dexbrompheniramine.Approved
DexchlorpheniramineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Dexchlorpheniramine.Experimental, Investigational
Dexchlorpheniramine maleateThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Dexchlorpheniramine maleate.Approved
DibenzepinThe risk or severity of hypertension can be increased when Dibenzepin is combined with Salbutamol.Experimental
DiflorasoneThe risk or severity of hypokalemia can be increased when Diflorasone is combined with Salbutamol.Approved
DifloxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Difloxacin.Vet Approved
DifluocortoloneThe risk or severity of hypokalemia can be increased when Difluocortolone is combined with Salbutamol.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of hypokalemia can be increased when Difluprednate is combined with Salbutamol.Approved
DihydroergocornineDihydroergocornine may increase the hypertensive and vasoconstricting activities of Salbutamol.Approved
DihydroergocristineDihydroergocristine may increase the hypertensive and vasoconstricting activities of Salbutamol.Approved, Experimental
DihydroergocryptineDihydroergocryptine may increase the hypertensive and vasoconstricting activities of Salbutamol.Experimental
DihydroergotamineDihydroergotamine may increase the hypertensive and vasoconstricting activities of Salbutamol.Approved, Investigational
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Dimenhydrinate.Approved
DimetacrineThe risk or severity of hypertension can be increased when Dimetacrine is combined with Salbutamol.Approved, Withdrawn
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Diphenhydramine.Approved, Investigational
DipivefrinThe risk or severity of adverse effects can be increased when Salbutamol is combined with Dipivefrin.Approved
DisopyramideThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Disopyramide.Approved
DobutamineThe risk or severity of adverse effects can be increased when Salbutamol is combined with Dobutamine.Approved
DofetilideThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Dofetilide.Approved, Investigational
DolasetronThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Dolasetron.Approved, Investigational
DomperidoneThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Domperidone.Approved, Investigational, Vet Approved
DonepezilThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Donepezil.Approved
DosulepinThe risk or severity of hypertension can be increased when Dosulepin is combined with Salbutamol.Approved
DoxazosinThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Doxazosin.Approved
DoxepinThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Doxepin.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Doxofylline is combined with Salbutamol.Approved, Investigational
DoxylamineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Doxylamine.Approved, Vet Approved
DronedaroneThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Dronedarone.Approved
DroperidolThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Droperidol.Approved, Vet Approved
DroxidopaThe risk or severity of adverse effects can be increased when Salbutamol is combined with Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the tachycardic activities of Salbutamol.Approved
EbastineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ebastine.Approved, Investigational
EliglustatThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Eliglustat.Approved
EmedastineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Emedastine.Approved
EnoxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Enoxacin.Approved, Investigational
EntinostatThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Entinostat.Investigational
EpanololThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Salbutamol is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinastineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Epinastine.Approved, Investigational
EpinephrineThe risk or severity of adverse effects can be increased when Salbutamol is combined with Epinephrine.Approved, Vet Approved
EpitizideSalbutamol may increase the hypokalemic activities of Epitizide.Experimental
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Salbutamol.Approved
ErgonovineErgonovine may increase the hypertensive and vasoconstricting activities of Salbutamol.Approved
ErgotamineErgotamine may increase the hypertensive and vasoconstricting activities of Salbutamol.Approved
EribulinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Eribulin.Approved, Investigational
ErlotinibThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Erlotinib.Approved, Investigational
ErythromycinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Esatenolol.Experimental
EscitalopramThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Escitalopram.Approved, Investigational
EsmololThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Esmolol.Approved
Etacrynic acidThe risk or severity of hyperkalemia can be increased when Salbutamol is combined with Etacrynic acid.Approved, Investigational
EtafedrineThe risk or severity of adverse effects can be increased when Salbutamol is combined with Etafedrine.Approved
EzogabineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ezogabine.Approved, Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Salbutamol.Approved
FelbamateThe risk or severity of QTc prolongation can be increased when Felbamate is combined with Salbutamol.Approved
FenoterolThe risk or severity of adverse effects can be increased when Salbutamol is combined with Fenoterol.Approved, Investigational
FexofenadineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Fexofenadine.Approved, Investigational
FingolimodThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Fingolimod.Approved, Investigational
FlecainideThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Flecainide.Approved, Withdrawn
FleroxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Fleroxacin.Approved
FlucloroloneThe risk or severity of hypokalemia can be increased when Fluclorolone is combined with Salbutamol.Experimental
FluconazoleThe risk or severity of QTc prolongation can be increased when Fluconazole is combined with Salbutamol.Approved, Investigational
FludrocortisoneThe risk or severity of hypokalemia can be increased when Fludrocortisone is combined with Salbutamol.Approved, Investigational
FlumequineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Flumequine.Withdrawn
FlumethasoneThe risk or severity of hypokalemia can be increased when Flumethasone is combined with Salbutamol.Approved, Vet Approved
FlunisolideThe risk or severity of hypokalemia can be increased when Flunisolide is combined with Salbutamol.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of hypokalemia can be increased when Fluocinolone Acetonide is combined with Salbutamol.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of hypokalemia can be increased when Fluocinonide is combined with Salbutamol.Approved, Investigational
FluocortinThe risk or severity of hypokalemia can be increased when Fluocortin is combined with Salbutamol.Experimental
FluocortoloneThe risk or severity of hypokalemia can be increased when Fluocortolone is combined with Salbutamol.Approved, Withdrawn
FluorometholoneThe risk or severity of hypokalemia can be increased when Fluorometholone is combined with Salbutamol.Approved, Investigational
FluoxetineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Flupentixol.Approved, Investigational, Withdrawn
FluperoloneThe risk or severity of hypokalemia can be increased when Fluperolone is combined with Salbutamol.Experimental
FluprednideneThe risk or severity of hypokalemia can be increased when Fluprednidene is combined with Salbutamol.Approved, Withdrawn
FluprednisoloneThe risk or severity of hypokalemia can be increased when Fluprednisolone is combined with Salbutamol.Approved
FlurandrenolideThe risk or severity of hypokalemia can be increased when Flurandrenolide is combined with Salbutamol.Approved
FluticasoneThe risk or severity of hypokalemia can be increased when Fluticasone is combined with Salbutamol.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of hypokalemia can be increased when Fluticasone furoate is combined with Salbutamol.Approved
Fluticasone propionateThe risk or severity of hypokalemia can be increased when Fluticasone propionate is combined with Salbutamol.Approved
FormocortalThe risk or severity of hypokalemia can be increased when Formocortal is combined with Salbutamol.Experimental
FormoterolThe risk or severity of adverse effects can be increased when Formoterol is combined with Salbutamol.Approved, Investigational
FoscarnetThe risk or severity of QTc prolongation can be increased when Foscarnet is combined with Salbutamol.Approved
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Salbutamol.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of hyperkalemia can be increased when Salbutamol is combined with Furosemide.Approved, Vet Approved
Gadobenic acidThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Gadobenic acid.Approved, Investigational
GalantamineThe risk or severity of QTc prolongation can be increased when Galantamine is combined with Salbutamol.Approved
GarenoxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Gemifloxacin.Approved, Investigational
GivinostatThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Givinostat.Investigational
GoserelinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Goserelin.Approved
GranisetronThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Granisetron.Approved, Investigational
GrepafloxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Grepafloxacin.Approved, Investigational, Withdrawn
HalcinonideThe risk or severity of hypokalemia can be increased when Halcinonide is combined with Salbutamol.Approved, Investigational, Withdrawn
HalofantrineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Halofantrine.Approved
HalometasoneThe risk or severity of hypokalemia can be increased when Halometasone is combined with Salbutamol.Experimental
HaloperidolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Haloperidol.Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Salbutamol.Experimental
HexoprenalineThe risk or severity of adverse effects can be increased when Salbutamol is combined with Hexoprenaline.Approved, Withdrawn
HistrelinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Histrelin.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Salbutamol.Experimental
HydrochlorothiazideSalbutamol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Salbutamol.Approved, Vet Approved
Hydrocortisone aceponateThe risk or severity of hypokalemia can be increased when Hydrocortisone aceponate is combined with Salbutamol.Experimental, Vet Approved
Hydrocortisone acetateThe risk or severity of hypokalemia can be increased when Hydrocortisone acetate is combined with Salbutamol.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of hypokalemia can be increased when Hydrocortisone butyrate is combined with Salbutamol.Approved, Vet Approved
Hydrocortisone probutateThe risk or severity of hypokalemia can be increased when Hydrocortisone probutate is combined with Salbutamol.Approved, Vet Approved
Hydrocortisone succinateThe risk or severity of hypokalemia can be increased when Hydrocortisone succinate is combined with Salbutamol.Approved
Hydrocortisone valerateThe risk or severity of hypokalemia can be increased when Hydrocortisone valerate is combined with Salbutamol.Approved, Vet Approved
HydroflumethiazideSalbutamol may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydroxychloroquineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Hydroxychloroquine.Approved
HydroxyzineThe risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Salbutamol.Approved
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Salbutamol.Approved, Investigational
IbutilideThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ibutilide.Approved
IloperidoneThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Iloperidone.Approved
ImatinibThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Imatinib.Approved
ImipramineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Imipramine.Approved
Imipramine oxideThe risk or severity of hypertension can be increased when Imipramine oxide is combined with Salbutamol.Experimental
IndacaterolThe risk or severity of adverse effects can be increased when Salbutamol is combined with Indacaterol.Approved
IndapamideSalbutamol may increase the hypokalemic activities of Indapamide.Approved
IndenololThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Indenolol.Withdrawn
IndoraminThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Indoramin.Withdrawn
IprindoleThe risk or severity of hypertension can be increased when Iprindole is combined with Salbutamol.Experimental
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Salbutamol.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Salbutamol.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Salbutamol is combined with Isoetarine.Approved
IsofluraneThe risk or severity of QTc prolongation can be increased when Isoflurane is combined with Salbutamol.Approved, Vet Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Salbutamol is combined with Isoprenaline.Approved, Investigational
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Salbutamol.Approved, Investigational
ItraconazoleThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Itraconazole.Approved, Investigational
IvabradineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ivabradine.Approved
IvosidenibThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ivosidenib.Approved, Investigational
KetoconazoleThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ketoconazole.Approved, Investigational
KetotifenThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ketotifen.Approved
LabetalolThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Labetalol.Approved
LandiololThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Landiolol.Investigational
LapatinibThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Lapatinib.Approved, Investigational
LenvatinibThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Lenvatinib.Approved, Investigational
LeuprolideThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Leuprolide.Approved, Investigational
LevobetaxololThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Levobetaxolol.Approved, Investigational
LevobunololThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Levobunolol.Approved
LevocabastineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Levocetirizine.Approved
LevofloxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Salbutamol.Approved, Investigational
LevosalbutamolThe risk or severity of adverse effects can be increased when Salbutamol is combined with Levosalbutamol.Approved, Investigational
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Salbutamol.Approved, Investigational
LisurideLisuride may increase the hypertensive and vasoconstricting activities of Salbutamol.Approved, Investigational
Lithium cationThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Lithium cation.Experimental
LofepramineThe risk or severity of hypertension can be increased when Lofepramine is combined with Salbutamol.Experimental
LomefloxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Lomefloxacin.Approved, Investigational
LopinavirThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Lopinavir.Approved
LoratadineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Loratadine.Approved, Investigational
LoteprednolThe risk or severity of hypokalemia can be increased when Loteprednol is combined with Salbutamol.Approved
LoxapineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Loxapine.Approved
LumefantrineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Lumefantrine.Approved
Lysergic Acid DiethylamideLysergic Acid Diethylamide may increase the hypertensive and vasoconstricting activities of Salbutamol.Illicit, Investigational, Withdrawn
MacimorelinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Macimorelin.Approved, Investigational
MaprotilineThe risk or severity of QTc prolongation can be increased when Maprotiline is combined with Salbutamol.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Salbutamol.Withdrawn
MedrysoneThe risk or severity of hypokalemia can be increased when Medrysone is combined with Salbutamol.Approved
MefloquineThe risk or severity of QTc prolongation can be increased when Mefloquine is combined with Salbutamol.Approved, Investigational
MelengestrolThe risk or severity of hypokalemia can be increased when Melengestrol is combined with Salbutamol.Vet Approved
MelitracenThe risk or severity of hypertension can be increased when Melitracen is combined with Salbutamol.Experimental, Investigational
MepindololMepindolol may decrease the bronchodilatory activities of Salbutamol.Experimental
MeprednisoneThe risk or severity of hypokalemia can be increased when Meprednisone is combined with Salbutamol.Approved, Investigational
MepyramineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Mepyramine.Approved, Vet Approved
MequitazineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Mequitazine.Approved
MesoridazineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Mesoridazine.Approved, Investigational
MetergolineMetergoline may increase the hypertensive and vasoconstricting activities of Salbutamol.Experimental
MethadoneThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Methadone.Approved
MethotrimeprazineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
MethyclothiazideSalbutamol may increase the hypokalemic activities of Methyclothiazide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Salbutamol.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Salbutamol.Approved
MethylprednisoloneThe risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Salbutamol.Approved, Vet Approved
MethysergideMethysergide may increase the hypertensive and vasoconstricting activities of Salbutamol.Approved
MetipranololThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Metipranolol.Approved
MetoclopramideThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Metoclopramide.Approved, Investigational
MetolazoneSalbutamol may increase the hypokalemic activities of Metolazone.Approved
MetoprololThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Metoprolol.Approved, Investigational
MetronidazoleThe risk or severity of QTc prolongation can be increased when Metronidazole is combined with Salbutamol.Approved
MifepristoneThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the tachycardic activities of Salbutamol.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Salbutamol.Approved
MirabegronThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Mirabegron.Approved
MirtazapineThe risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Salbutamol.Approved
MocetinostatThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Mocetinostat.Investigational
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Salbutamol.Approved, Investigational
MoexiprilThe risk or severity of QTc prolongation can be increased when Moexipril is combined with Salbutamol.Approved
MometasoneThe risk or severity of hypokalemia can be increased when Mometasone is combined with Salbutamol.Approved, Vet Approved
Mometasone furoateThe risk or severity of hypokalemia can be increased when Mometasone furoate is combined with Salbutamol.Approved, Vet Approved
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Moxifloxacin.Approved, Investigational
NadololNadolol may decrease the bronchodilatory activities of Salbutamol.Approved
Nalidixic AcidThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Nalidixic Acid.Approved, Investigational
NebivololThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Nebivolol.Approved, Investigational
NefazodoneThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Nefazodone.Approved, Withdrawn
NelfinavirThe risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Salbutamol.Approved
NemonoxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Nemonoxacin.Investigational
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Salbutamol.Withdrawn
NicardipineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Nicardipine.Approved, Investigational
NicergolineNicergoline may increase the hypertensive and vasoconstricting activities of Salbutamol.Approved, Investigational
NiguldipineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Niguldipine.Experimental
NilotinibThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Nilotinib.Approved, Investigational
NorepinephrineThe risk or severity of adverse effects can be increased when Salbutamol is combined with Norepinephrine.Approved
NorfloxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Norfloxacin.Approved
NortriptylineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Nortriptyline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Salbutamol.Withdrawn
OctreotideThe risk or severity of QTc prolongation can be increased when Octreotide is combined with Salbutamol.Approved, Investigational
OfloxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ofloxacin.Approved
OlanzapineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Olanzapine.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Salbutamol is combined with Olodaterol.Approved
OlopatadineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Olopatadine.Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ondansetron.Approved
OpipramolThe risk or severity of hypertension can be increased when Opipramol is combined with Salbutamol.Investigational
OrbifloxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Orbifloxacin.Vet Approved
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Salbutamol.Approved
OrphenadrineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Orphenadrine.Approved
OxaliplatinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Oxaliplatin.Approved, Investigational
OxaprotilineThe risk or severity of hypertension can be increased when Oxaprotiline is combined with Salbutamol.Experimental
OxatomideThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Oxatomide.Investigational
Oxolinic acidThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Oxolinic acid.Experimental
OxprenololOxprenolol may decrease the bronchodilatory activities of Salbutamol.Approved
OxytocinThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Salbutamol.Approved, Vet Approved
PaliperidoneThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Paliperidone.Approved
PanobinostatThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Papaverine.Approved, Investigational
ParamethasoneThe risk or severity of hypokalemia can be increased when Paramethasone is combined with Salbutamol.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Salbutamol.Approved
ParoxetineThe risk or severity of QTc prolongation can be increased when Paroxetine is combined with Salbutamol.Approved, Investigational
PasireotideThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Pasireotide.Approved
PazopanibThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Pazopanib.Approved
PazufloxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Pefloxacin.Approved
PenbutololPenbutolol may decrease the bronchodilatory activities of Salbutamol.Approved, Investigational
PentamidineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Pentamidine.Approved, Investigational
PerflutrenThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Perflutren.Approved
PergolidePergolide may increase the hypertensive and vasoconstricting activities of Salbutamol.Approved, Investigational, Vet Approved, Withdrawn
PF-00610355The risk or severity of adverse effects can be increased when Salbutamol is combined with PF-00610355.Investigational
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Salbutamol.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Salbutamol.Withdrawn
PheniramineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Pheniramine.Approved
PhenoxybenzamineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Phenoxybenzamine.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Salbutamol.Withdrawn
PhentolamineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Phentolamine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Salbutamol is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PimozideThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Pimozide.Approved
PindololPindolol may decrease the bronchodilatory activities of Salbutamol.Approved, Investigational
Pipemidic acidThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Pipemidic acid.Experimental
PirbuterolThe risk or severity of adverse effects can be increased when Salbutamol is combined with Pirbuterol.Approved
PiretanideThe risk or severity of hyperkalemia can be increased when Salbutamol is combined with Piretanide.Approved
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Salbutamol.Approved
Piromidic acidThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Piromidic acid.Experimental
PitolisantThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Pitolisant.Approved, Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Salbutamol.Withdrawn
PizotifenThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Pizotifen.Approved
PolythiazideSalbutamol may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Posaconazole.Approved, Investigational, Vet Approved
PracinostatThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Pracinostat.Investigational
PractololThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Practolol.Approved
PrazosinThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Prazosin.Approved
PrednicarbateThe risk or severity of hypokalemia can be increased when Prednicarbate is combined with Salbutamol.Approved, Investigational
PrednisoloneThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Salbutamol.Approved, Vet Approved
PrednisoneThe risk or severity of hypokalemia can be increased when Prednisone is combined with Salbutamol.Approved, Vet Approved
PrednylideneThe risk or severity of hypokalemia can be increased when Prednylidene is combined with Salbutamol.Experimental
PrimaquineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Primaquine.Approved
ProbucolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Probucol.Approved, Investigational
ProcainamideThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Procainamide.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Salbutamol is combined with Procaterol.Approved, Investigational
PromazineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Promethazine.Approved, Investigational
PropafenoneThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Propafenone.Approved
PropericiazineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Propericiazine.Approved, Investigational
PropiomazineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Propiomazine.Approved
PropiverineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Propiverine.Approved, Investigational
PropofolThe risk or severity of QTc prolongation can be increased when Propofol is combined with Salbutamol.Approved, Investigational, Vet Approved
PropranololPropranolol may decrease the bronchodilatory activities of Salbutamol.Approved, Investigational
ProtokylolThe risk or severity of adverse effects can be increased when Salbutamol is combined with Protokylol.Approved, Vet Approved
ProtriptylineThe risk or severity of hypertension can be increased when Protriptyline is combined with Salbutamol.Approved
PrulifloxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Prulifloxacin.Investigational
QuetiapineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Quetiapine.Approved
QuinethazoneSalbutamol may increase the hypokalemic activities of Quinethazone.Approved
QuinidineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Quinidine.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Quinine.Approved
QuinupramineThe risk or severity of hypertension can be increased when Quinupramine is combined with Salbutamol.Experimental
RacepinephrineThe risk or severity of adverse effects can be increased when Salbutamol is combined with Racepinephrine.Approved
RanolazineThe risk or severity of QTc prolongation can be increased when Ranolazine is combined with Salbutamol.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Salbutamol.Approved
RibociclibThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ribociclib.Approved, Investigational
RicolinostatThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ricolinostat.Investigational
RilpivirineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Rilpivirine.Approved
RimexoloneThe risk or severity of hypokalemia can be increased when Rimexolone is combined with Salbutamol.Approved
RisperidoneThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Risperidone.Approved, Investigational
RitodrineThe risk or severity of adverse effects can be increased when Salbutamol is combined with Ritodrine.Approved, Investigational
RitonavirThe risk or severity of QTc prolongation can be increased when Ritonavir is combined with Salbutamol.Approved, Investigational
RomidepsinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Romidepsin.Approved, Investigational
RosoxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Rosoxacin.Approved, Investigational
RoxithromycinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Roxithromycin.Approved, Investigational, Withdrawn
RufloxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Rufloxacin.Experimental
RupatadineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Rupatadine.Approved
SafinamideThe risk or severity of adverse effects can be increased when Safinamide is combined with Salbutamol.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Salbutamol.Withdrawn
SalmeterolThe risk or severity of adverse effects can be increased when Salmeterol is combined with Salbutamol.Approved
SaquinavirThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Saquinavir.Approved, Investigational
SarafloxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Sarafloxacin.Vet Approved, Withdrawn
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Salbutamol.Approved, Investigational, Vet Approved
SertralineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Sertraline.Approved
SevofluraneThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Sevoflurane.Approved, Vet Approved
SibutramineSibutramine may increase the tachycardic activities of Salbutamol.Approved, Illicit, Investigational, Withdrawn
SilodosinThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Silodosin.Approved
SitafloxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Sitafloxacin.Experimental, Investigational
SolifenacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Solifenacin.Approved
SorafenibThe risk or severity of QTc prolongation can be increased when Sorafenib is combined with Salbutamol.Approved, Investigational
SotalolSotalol may decrease the bronchodilatory activities of Salbutamol.Approved
SparfloxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Sparfloxacin.Approved, Investigational
SpironolactoneThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Spironolactone.Approved
SulfamethoxazoleThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Sulfamethoxazole.Approved
SulfisoxazoleThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Sultopride.Experimental
SunitinibThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Sunitinib.Approved, Investigational
TalinololThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Talinolol.Investigational
TamoxifenThe risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Salbutamol.Approved
TamsulosinThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Tamsulosin.Approved, Investigational
TandutinibThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Tandutinib.Investigational
Technetium Tc-99m ciprofloxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Technetium Tc-99m ciprofloxacin.Investigational
TelavancinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Telavancin.Approved
TelithromycinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Temafloxacin.Withdrawn
TerazosinThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Terazosin.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Salbutamol is combined with Terbutaline.Approved
TerfenadineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Terfenadine.Approved, Withdrawn
TergurideTerguride may increase the hypertensive and vasoconstricting activities of Salbutamol.Experimental
TerlipressinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Terlipressin.Approved, Investigational
TerodilineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Terodiline.Experimental
TertatololTertatolol may decrease the bronchodilatory activities of Salbutamol.Experimental
TetrabenazineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Tetrabenazine.Approved, Investigational
ThioproperazineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Thioproperazine.Approved
ThioridazineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Thiothixene.Approved
TianeptineThe risk or severity of hypertension can be increased when Tianeptine is combined with Salbutamol.Approved, Investigational
TimololTimolol may decrease the bronchodilatory activities of Salbutamol.Approved
TixocortolThe risk or severity of hypokalemia can be increased when Tixocortol is combined with Salbutamol.Approved, Withdrawn
TizanidineThe risk or severity of QTc prolongation can be increased when Tizanidine is combined with Salbutamol.Approved, Investigational
TolazolineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Tolazoline.Approved, Vet Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Salbutamol.Approved
TolterodineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Tolterodine.Approved, Investigational
TorasemideThe risk or severity of hyperkalemia can be increased when Salbutamol is combined with Torasemide.Approved
ToremifeneThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Toremifene.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Salbutamol.Approved, Investigational
TrazodoneThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Trazodone.Approved, Investigational
TreprostinilThe risk or severity of QTc prolongation can be increased when Treprostinil is combined with Salbutamol.Approved, Investigational
TriamcinoloneThe risk or severity of hypokalemia can be increased when Triamcinolone is combined with Salbutamol.Approved, Vet Approved
TrichlormethiazideSalbutamol may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Trifluoperazine.Approved, Investigational
TrilostaneThe risk or severity of hypokalemia can be increased when Trilostane is combined with Salbutamol.Approved, Investigational, Vet Approved, Withdrawn
TrimazosinThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Trimazosin.Experimental
TrimethoprimThe risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Salbutamol.Approved, Vet Approved
TrimipramineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Trimipramine.Approved
TriprolidineThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Triprolidine.Approved
TriptorelinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Triptorelin.Approved, Vet Approved
TrovafloxacinThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TucidinostatThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Tucidinostat.Investigational
UlobetasolThe risk or severity of hypokalemia can be increased when Ulobetasol is combined with Salbutamol.Approved
UrapidilThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Urapidil.Investigational
Valproic AcidThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Valproic Acid.Approved, Investigational
VandetanibThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Vandetanib.Approved
VardenafilThe risk or severity of QTc prolongation can be increased when Vardenafil is combined with Salbutamol.Approved
VenlafaxineVenlafaxine may increase the tachycardic activities of Salbutamol.Approved
VerapamilThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Verapamil.Approved
VilanterolThe risk or severity of adverse effects can be increased when Salbutamol is combined with Vilanterol.Approved
VoriconazoleThe risk or severity of QTc prolongation can be increased when Voriconazole is combined with Salbutamol.Approved, Investigational
VorinostatThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Vorinostat.Approved, Investigational
ZiprasidoneThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ziprasidone.Approved
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Toshikuni Kawazi, Masahiro Ono, Nobuko Inoue, "Salbutamol-containing plaster and method of producing same." U.S. Patent US5068103, issued February, 1984.

US5068103
General References
Not Available
External Links
Human Metabolome Database
HMDB0001937
KEGG Drug
D02147
PubChem Compound
2083
PubChem Substance
46505312
ChemSpider
1999
BindingDB
25769
ChEBI
2549
ChEMBL
CHEMBL714
Therapeutic Targets Database
DNC000873
PharmGKB
PA448068
IUPHAR
558
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Wikipedia
Salbutamol
ATC Codes
R03AL02 — Salbutamol and ipratropium bromideR03AK04 — Salbutamol and sodium cromoglicateR03CC02 — SalbutamolR03AC02 — Salbutamol
AHFS Codes
  • 12:12.08.12 — Selective Beta 2-adrenergic Agonists
  • 12:12.00 — Sympathomimetic (Adrenergic) Agents
MSDS
Download (52.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceHealthy Volunteers1
1CompletedNot AvailableHealthy Volunteers3
1CompletedBasic SciencePulmonary Disease, Chronic Obstructive1
1CompletedDiagnosticAirway Inflammation1
1CompletedDiagnosticPulmonary Disease, Chronic Obstructive1
1CompletedDiagnosticSickle Cell Disorders1
1CompletedTreatmentAsthma Bronchial1
1CompletedTreatmentAsthma Bronchial / Diabetes Mellitus (DM)1
1CompletedTreatmentAsthma, Allergic1
1CompletedTreatmentCongenital Myasthenic Syndrome1
1CompletedTreatmentDiabetes Mellitus (DM) / Healthy Volunteers1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
1CompletedTreatmentMajor Depressive Disorder (MDD)1
1CompletedTreatmentPompe's Disease1
1RecruitingBasic ScienceCardiovascular System Disease / Drug-Related Side Effects and Adverse Reactions1
1RecruitingTreatmentAsthma Bronchial1
1RecruitingTreatmentStatus Asthmaticus1
1, 2CompletedTreatmentPompe's Disease1
2CompletedBasic ScienceMemory Functions1
2CompletedDiagnosticLung Diseases, Obstructive1
2CompletedTreatmentAsthma Bronchial16
2CompletedTreatmentAsthma Bronchial / Bronchospasm1
2CompletedTreatmentAsthma Bronchial / Efficacy / Safety1
2CompletedTreatmentBrain Death / Organ Donors / Pulmonary Edemas1
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
2CompletedTreatmentChronic Respiratory Failure / Clinically Significant Increase in Maximum Expiratory Volume Per Second1
2CompletedTreatmentPulmonary Disease, Chronic Obstructive2
2RecruitingTreatmentLymphangioleiomyomatosis1
2WithdrawnTreatmentAsthma Bronchial1
2WithdrawnTreatmentIdiopathic Pulmonary Arterial Hypertension1
2, 3CompletedTreatmentAllergies1
2, 3TerminatedTreatmentRespiratory Distress Syndrome, Adult1
2, 3WithdrawnTreatmentCongestive Heart Failure (CHF)1
3Active Not RecruitingTreatmentAsthma Bronchial2
3Active Not RecruitingTreatmentRhinitis, Allergic, Seasonal1
3CompletedTreatmentAllergies / Conjunctivitis / Rhinitis / Rhinoconjunctivitis2
3CompletedTreatmentAsthma Bronchial19
3CompletedTreatmentAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)1
3CompletedTreatmentBronchial Asthma2
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)7
3CompletedTreatmentCongestive Heart Failure (CHF) / Heart Failure, Left-Sided / Left-Sided Heart Failure1
3CompletedTreatmentOrganophosphate Poisoning1
3CompletedTreatmentPersistent Asthma2
3CompletedTreatmentPulmonary Disease, Chronic Obstructive5
3CompletedTreatmentReactive Airways Disease (RAD)1
3Not Yet RecruitingTreatmentAsthma Bronchial2
3Not Yet RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD) / High-flow Nasal Cannula1
3RecruitingTreatmentAsthma Bronchial1
3RecruitingTreatmentAsthma, Allergic1
3RecruitingTreatmentBronchial Asthma1
3TerminatedPreventionAsthma Bronchial / Bronchospasm1
3TerminatedTreatmentAsthma Bronchial1
3Unknown StatusTreatmentPulmonary Disease, Chronic Obstructive1
3WithdrawnTreatmentAsthma Bronchial1
3WithdrawnTreatmentAsthma Bronchial / Chronic Lung Diseases1
3WithdrawnTreatmentPulmonary Disease, Chronic Obstructive1
4Active Not RecruitingTreatmentAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD) / Healthy Volunteers1
4CompletedNot AvailableAsthma Bronchial2
4CompletedBasic ScienceAsthma Bronchial1
4CompletedBasic ScienceBronchoconstriction / Cycling Performance / Exercise-Induced Bronchoconstriction (EIB) / Inhaled Salbutamol1
4CompletedDiagnosticAsthma Bronchial1
4CompletedDiagnosticObliterative Bronchiolitis1
4CompletedHealth Services ResearchAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)1
4CompletedPreventionAsthma Bronchial / Heart Rate Fast1
4CompletedSupportive CareAsthma Bronchial1
4CompletedSupportive CareChronic Obstructive Pulmonary Disease (COPD) / Sepsis / Shock1
4CompletedTreatmentAsthma Acute / Asthma Bronchial / Reactive Airway Exacerbation1
4CompletedTreatmentAsthma Bronchial11
4CompletedTreatmentChildhood Asthma1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)2
4CompletedTreatmentMechanically Ventilated Patients1
4CompletedTreatmentPompe's Disease1
4CompletedTreatmentPulmonary Disease, Chronic Obstructive4
4CompletedTreatmentVentricular Septal Defects1
4Not Yet RecruitingTreatmentPulmonary Disease, Chronic Obstructive1
4RecruitingPreventionAsthma in Children / Exercise Induced Bronchospasm / Obesity, Childhood1
4RecruitingTreatmentAir Trapping / Airflow Limitation / Hyperinflation / Obstructive Lung Diseases / Secondhand Smoke / Tobacco1
4RecruitingTreatmentAsthma Bronchial1
4RecruitingTreatmentAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentAsthmatic Bronchitis / Obstruction Airway / Wheezing / Wheezy Bronchitis1
4RecruitingTreatmentChildhood Asthma With Status Asthmaticus1
4RecruitingTreatmentPulmonary Disease, Chronic Obstructive2
4TerminatedTreatmentAsthma Acute1
4TerminatedTreatmentAsthma Bronchial1
4TerminatedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4Unknown StatusDiagnosticChronic Lung Disease of Prematurity / Very Low Birth Weight1
4Unknown StatusPreventionCesarean Section / Postnatal Pulmonary Adaptation1
4Unknown StatusTreatmentAsthma Bronchial1
4Unknown StatusTreatmentBronchial Asthma1
4Unknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4WithdrawnTreatmentAsthma Bronchial2
4WithdrawnTreatmentWheezing1
Not AvailableActive Not RecruitingTreatmentAsthma Bronchial1
Not AvailableCompletedNot AvailableAsthma Bronchial / Chronic Bronchitis / Chronic Obstructive Pulmonary Disease (COPD) / Emphysema1
Not AvailableCompletedBasic ScienceAdrenergic Beta-2 Agonist Effect / Adrenergic Beta-2 Agonist Effect in Healthy Subjects / Albuterol Effect / Albuterol Effect in Healthy Subjects1
Not AvailableCompletedBasic ScienceCystic Fibrosis (CF) / Healthy Volunteers1
Not AvailableCompletedBasic ScienceMuscle Hypertrophy in Healthy Young Men1
Not AvailableCompletedBasic ScienceOxygen Consumption1
Not AvailableCompletedDiagnosticAsthma Bronchial1
Not AvailableCompletedDiagnosticBronchodilation1
Not AvailableCompletedDiagnosticChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedDiagnosticHematopoietic Stem Cell Transplantation (HSCT) / Obliterative Bronchiolitis1
Not AvailableCompletedHealth Services ResearchAsthma Bronchial1
Not AvailableCompletedHealth Services ResearchChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedOtherAirway Disease Small / Hypersensitivity Pneumonitis1
Not AvailableCompletedTreatmentAsthma Acute / Moderate and Severe Acute Asthma Exacerbations in Pediatric Patients1
Not AvailableCompletedTreatmentAsthma Bronchial2
Not AvailableCompletedTreatmentAsthma Bronchial / Children1
Not AvailableCompletedTreatmentAsthma Placebo Effects1
Not AvailableCompletedTreatmentAutoimmune Diseases / Disseminated Sclerosis1
Not AvailableCompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedTreatmentMuscular Dystrophy1
Not AvailableCompletedTreatmentMuscular Dystrophy, Facioscapulohumeral1
Not AvailableCompletedTreatmentPneumonia1
Not AvailableCompletedTreatmentRespiratory Failure1
Not AvailableNot Yet RecruitingNot AvailableAsthma Bronchial1
Not AvailableNot Yet RecruitingNot AvailablePulmonary Disease, Chronic Obstructive1
Not AvailableNot Yet RecruitingDiagnosticChildhood Asthma1
Not AvailableNot Yet RecruitingSupportive CareChronic Lung Diseases / Cystic Fibrosis (CF)1
Not AvailableRecruitingNot AvailableAAT Deficiency / AATD / Alpha-1 Antitrypsin Deficiency / Cystic Fibrosis (CF)1
Not AvailableRecruitingNot AvailableAortic Valve Stenosis / Hypertension,Essential / Impaired Renal Function / Secondary Hypertension1
Not AvailableRecruitingNot AvailableAsthma Bronchial / Food Allergy / Obstructive Sleep Apnea (OSA) / Viruses / Wheezing1
Not AvailableRecruitingHealth Services ResearchAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)1
Not AvailableRecruitingTreatmentAsthma Bronchial2
Not AvailableRecruitingTreatmentAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)1
Not AvailableRecruitingTreatmentHigh Flow Nasal Cannula1
Not AvailableRecruitingTreatmentRespiratory Muscle Weakness / Spinal Cord Injuries (SCI)1
Not AvailableRecruitingTreatmentSevere Bronchopulmonary Dysplasia1
Not AvailableSuspendedTreatmentCystic Fibrosis (CF)1
Not AvailableTerminatedBasic ScienceChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableUnknown StatusNot AvailableAsthma Bronchial1
Not AvailableUnknown StatusNot AvailableChronic Obstructive Pulmonary Disease (COPD) / Emphysema1
Not AvailableUnknown StatusNot AvailableElectrophysiological Parameters / Influence of Nebulized Bronchodilatators on Selected1
Not AvailableUnknown StatusNot AvailableErgogenic Effects of Salbutamol in Healthy Males1
Not AvailableUnknown StatusDiagnosticTuberculosis1
Not AvailableUnknown StatusTreatmentAsthma Bronchial1
Not AvailableUnknown StatusTreatmentBronchiolitis1
Not AvailableUnknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD)2
Not AvailableUnknown StatusTreatmentHeart Failure, Unspecified / Ischaemic Cardiomyopathy / Non-ischaemic Cardiomyopathy1

Pharmacoeconomics

Manufacturers
  • Armstrong pharmaceuticals inc
  • Genpharm inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Pliva inc
  • Schering corp sub schering plough corp
  • Glaxosmithkline
  • Teva global respiratory research llc
  • 3m pharmaceuticals inc
  • Dey lp
  • Actavis mid atlantic llc
  • Apotex inc richmond hill
  • Apotex inc
  • Bausch and lomb inc
  • Cobalt laboratories inc
  • Copley pharmaceutical inc
  • Hi tech pharmacal co inc
  • Holopack international
  • Landela pharmaceutical
  • Nephron pharmaceuticals corp
  • Nephron corp
  • Novex pharma
  • Roxane laboratories inc
  • Teva parenteral medicines inc
  • Watson laboratories inc
  • Wockhardt eu operations (swiss) ag
  • Amneal pharmaceuticals
  • Mova pharmaceuticals corp
  • Teva pharmaceuticals usa inc
  • Vintage pharmaceuticals llc
  • Vistapharm inc
  • Mylan pharmaceuticals inc
  • Muro pharmaceutical inc
  • Dava pharmaceuticals inc
  • American therapeutics inc
  • Mutual pharmaceutical co inc
  • Sandoz inc
  • Ucb inc
  • Warner chilcott div warner lambert co
  • Breath ltd
  • Sepracor inc
  • Teva Pharmaceuticals
Packagers
  • 3M Health Care
  • Actavis Group
  • Advanced Pharmaceutical Services Inc.
  • Amerisource Health Services Corp.
  • Apotheca Inc.
  • Apothecon
  • Armstrong Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • Aslung Pharmaceutical Lp
  • Atlantic Biologicals Corporation
  • Automatic Liquid Packaging Inc.
  • Bausch & Lomb Inc.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Catalent Pharma Solutions
  • Charter Laboratories Inc.
  • Cipla Ltd.
  • Cobalt Pharmaceuticals Inc.
  • DAVA Pharmaceuticals
  • Dey Pharma LP
  • Direct Dispensing Inc.
  • DispenseXpress Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • GlaxoSmithKline Inc.
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Hi Tech Pharmacal Co. Inc.
  • Holopack International Corp.
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Major Pharmaceuticals
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mutual Pharmaceutical Co.
  • Mylan
  • Nephron Pharmaceuticals Corp.
  • Novopharm Ltd.
  • Nucare Pharmaceuticals Inc.
  • Odyssey Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • Patient First Corp.
  • PD-Rx Pharmaceuticals Inc.
  • Pharmedix
  • Physician Partners Ltd.
  • Physicians Total Care Inc.
  • Pliva Inc.
  • Prasco Labs
  • Preferred Pharmaceuticals Inc.
  • Qualitest
  • Quality Care
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Rx Elite
  • Sandhills Packaging Inc.
  • Schering Corp.
  • Sepracor Pharmaceuticals Inc.
  • Southwood Pharmaceuticals
  • Stratus Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • United Research Laboratories Inc.
  • Vintage Pharmaceuticals Inc.
  • Vistapharm Inc.
  • Warrick Pharmaceuticals Corp.
  • Watson Pharmaceuticals
Dosage forms
FormRouteStrength
Aerosol, meteredRespiratory (inhalation)100 mcg
Aerosol, meteredOral90 ug/1
TabletOral2 mg/1
TabletOral4 mg/1
SolutionIntrabronchial.63 mg/3mL
SolutionIntrabronchial1.25 mg/3mL
SolutionIntrabronchial2.5 mg/3mL
SolutionOral2 mg/5mL
SolutionRespiratory (inhalation).75 mg/3mL
SolutionRespiratory (inhalation).83 mg/mL
SolutionRespiratory (inhalation)1.5 mg/3mL
SolutionRespiratory (inhalation)2.5 mg/.5mL
SolutionRespiratory (inhalation)2.5 mg/3mL
SolutionRespiratory (inhalation)5 mg/mL
SyrupOcclusive dressing technique2 mg/5mL
SyrupOral2 mg/5mL
TabletOral2.4 mg/1
Tablet, film coated, extended releaseOral4 mg/1
Tablet, film coated, extended releaseOral8 mg/1
Tablet, extended releaseOral4 mg/1
Tablet, extended releaseOral8 mg/1
TabletOral2 mg
TabletOral4 mg
PowderRespiratory (inhalation)97 mcg
Aerosol, meteredOral; Respiratory (inhalation)
Spray, meteredRespiratory (inhalation)
InhalantRespiratory (inhalation)
SolutionRespiratory (inhalation)
SolutionRespiratory (inhalation)1.25 mg/.5mL
Aerosol, meteredOral100 mcg
SolutionOral0.4 mg
SolutionOral; Respiratory (inhalation)5 mg
Powder, meteredRespiratory (inhalation)90 ug/1
SolutionRespiratory (inhalation)0.5 mg
SolutionRespiratory (inhalation)5 mg
LiquidRespiratory (inhalation)1 mg
LiquidRespiratory (inhalation)0.05 %
LiquidRespiratory (inhalation)0.1 %
LiquidRespiratory (inhalation)0.2 %
SolutionRespiratory (inhalation)1 mg
SolutionRespiratory (inhalation)2 mg
PowderRespiratory (inhalation)200 mcg
PowderRespiratory (inhalation)400 mcg
Aerosol, meteredRespiratory (inhalation)108 ug/1
Aerosol, meteredRespiratory (inhalation)90 ug/1
SolutionIntramuscular0.5 mg
SolutionIntravenous0.25 mg
SolutionIntravenous1 mg
LiquidIntramuscular.5 mg
LiquidIntravenous1 mg
LiquidIntravenous.25 mg
SolutionRespiratory (inhalation)2.5 mg
LiquidRespiratory (inhalation)1.25 mg
LiquidRespiratory (inhalation)2.5 mg
SolutionRespiratory (inhalation)1.25 mg
LiquidRespiratory (inhalation)5 mg
LiquidOral0.4 mg
LiquidOral.4 mg
CapsuleRespiratory (inhalation)200 mcg
CapsuleRespiratory (inhalation)400 mcg
SolutionRespiratory (inhalation).31 mg/3mL
SolutionRespiratory (inhalation).63 mg/3mL
SolutionRespiratory (inhalation)1.25 mg/3mL
Solution, concentrateRespiratory (inhalation)1.25 mg/.5mL
Aerosol, meteredOral45 ug/1
Prices
Unit descriptionCostUnit
Xopenex 0.63 mg/3 ml solution64.2USD ml
Proventil HFA 108 (90 Base)mcg/act Aerosol 6.7 gm Inhaler55.09USD inhaler
Xopenex HFA 45 mcg/act Aerosol 15 gm Inhaler53.84USD inhaler
AccuNeb 0.63 mg/3ml Neb. Solution 1 Box= 25 Vials53.14USD plastic
AccuNeb 1.25 mg/3ml Neb. Solution 1 Box= 25 Vials53.14USD plastic
ProAir HFA 108 (90 Base)mcg/act Aerosol 8.5 gm Inhaler45.99USD inhaler
Ventolin HFA 108 (90 Base)mcg/act Aerosol 18 gm Inhaler39.99USD inhaler
Proair hfa 90 mcg inhaler12.62USD g
Proventil hfa 90 mcg inhaler8.07USD g
Xopenex hfa 45 mcg inhaler6.12USD g
Xopenex 0.31 mg/3ml (1 Box = 24, 3ml Vials)4.87USD plastic
Xopenex 1.25 mg/3ml (1 Box = 24, 3ml Vials)4.87USD plastic
Xopenex 0.63 mg/3ml (1 Box = 24, 3ml Vials)4.71USD plastic
Xopenex 1.25 mg/3 ml solution2.96USD ml
Ventolin hfa 90 mcg inhaler2.01USD g
Xopenex 0.31 mg/3 ml solution1.56USD ml
Ventolin 5 mg/ml Solution1.13USD ml
Ventolin Nebules P.F. 2 mg/ml Unit Dose Solution0.88USD ml
Accuneb 0.63 mg/3 ml inh solution0.68USD ml
Accuneb 1.25 mg/3 ml inh solution0.68USD ml
Mylan-Salbutamol 5 mg/ml Solution0.62USD ml
Pms-Salbutamol 5 mg/ml Solution0.62USD ml
Ratio-Salbutamol 5 mg/ml Solution0.62USD ml
Sandoz Salbutamol 5 mg/ml Solution0.62USD ml
Mylan-Salbutamol Sterinebs P.F. 2 mg/ml Unit Dose Solution0.48USD ml
Pms-Salbutamol Polyneb 2 mg/ml Unit Dose Solution0.48USD ml
Ratio-Salbutamol Uni Dose P.F. 2 mg/ml Unit Dose Solution0.48USD ml
Ventolin Nebules P.F. 1 mg/ml Solution0.47USD ml
Mylan-Salbutamol Sterinebs P.F. 1 mg/ml Solution0.25USD ml
Pms-Salbutamol 1 mg/ml Solution0.25USD ml
Ratio-Salbutamol Sulf U.D.P.F. 1 mg/ml Solution0.25USD ml
Apo-Salvent 4 mg Tablet0.22USD tablet
Pms-Salbutamol 0.5 mg/ml Solution0.16USD ml
Ratio-Salbutamol Unit Dose P.F 0.5 mg/ml Solution0.16USD ml
Apo-Salvent 2 mg Tablet0.13USD tablet
Pms-Salbutamol 400 mcg/ml Liquid0.05USD ml
Ratio-Salbutamol Hfa 100 mcg/dose Metered Dose Aerosol0.04USD dose
Airomir Cfc-Free 100 mcg/dose Metered Dose Aerosol0.03USD dose
Apo-Salvent Cfc Free 100 mcg/dose Metered Dose Aerosol0.03USD dose
Ventolin Hfa 100 mcg/dose Metered Dose Aerosol0.03USD dose
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6352684No1992-11-282009-11-28Us
CA2125667No2000-03-132012-12-04Canada
CA2125665No2001-06-122012-12-04Canada
US5775321No1995-07-072015-07-07Us
US6451289No2001-03-212021-03-21Us
US6446627No1997-12-182017-12-18Us
US6702997No2001-12-282021-12-28Us
US6632842No2001-12-282021-12-28Us
US6558651Yes1997-06-192017-06-19Us
US6743413Yes2001-12-012021-12-01Us
US6938796Yes1998-07-162018-07-16Us
US6997349Yes1998-07-162018-07-16Us
US6431168Yes1998-12-082018-12-08Us
US7107986Yes1998-12-062018-12-06Us
US7500444Yes2006-08-262026-08-26Us
US6315173Yes1998-06-232018-06-23Us
US7143908Yes1998-07-162018-07-16Us
US6170717Yes1998-06-232018-06-23Us
US7350676Yes1999-02-242019-02-24Us
US7832351Yes2003-12-192023-12-19Us
US6161724Yes1998-07-162018-07-16Us
US6510969Yes1998-06-232018-06-23Us
US6966467Yes1998-06-232018-06-23Us
US6435372Yes1998-07-162018-07-16Us
US7566445No1997-06-042017-06-04Us
US8834849No1997-06-042017-06-04Us
US7105152No2003-09-122023-09-12Us
US8132712No2008-09-072028-09-07Us
US6006745No1996-12-282016-12-28Us
US7256310No2004-10-082024-10-08Us
US8765153No2003-12-082023-12-08Us
US5836299No1995-11-172015-11-17Us
US6453795Yes1997-06-052017-06-05Us
US8733341Yes2011-04-162031-04-16Us
US9027967Yes2007-10-012027-10-01Us
US7104470Yes1997-04-042017-04-04Us
US7246615Yes1996-12-012016-12-01Us
US7896264Yes2005-11-262025-11-26Us
US7988001Yes2002-02-042022-02-04Us
US7802568Yes1999-08-262019-08-26Us
US6149054Yes1997-06-162017-06-16Us
US6726124Yes1997-04-042017-04-04Us
US7396341Yes2007-04-102027-04-10Us
US6846413Yes1999-02-282019-02-28Us
US6176442Yes1996-12-012016-12-01Us
US7837235Yes2008-09-132028-09-13Us
US5964416Yes1997-04-042017-04-04Us
US7284474Yes2005-02-262025-02-26Us
US6977042Yes1999-02-282019-02-28Us
US6988496Yes2000-08-232020-08-23Us
US6871646No2001-06-232021-06-23Us
US8978966No2012-01-132032-01-13Us
US6701917No2001-06-232021-06-23Us
US7540282No2003-05-062023-05-06Us
US6748947No2001-06-232021-06-23Us
US8006690No2001-06-232021-06-23Us
US6718972No2001-06-232021-06-23Us
US9216260No2011-06-282031-06-28Us
US8651103No2008-03-262028-03-26Us
US9463289No2011-05-182031-05-18Us
US9463288No2005-05-192025-05-19Us
US9731087No2011-05-182031-05-18Us
US9808587No2011-05-182031-05-18Us
US9861771No2000-10-112020-10-11Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)147-149Lunts, L.H.C. and Toon, P.; U.S. Patent 3,644,353; February 22,1972; assigned to Allen & Hanburys Ltd.
water solubility1.41E+004 mg/LYALKOWSKY,SH & HE,Y (2003)
logP1.4Not Available
logS-1.22ADME Research, USCD
pKa10.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.15 mg/mLALOGPS
logP0.44ALOGPS
logP0.34ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)10.12ChemAxon
pKa (Strongest Basic)9.4ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area72.72 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity67.87 m3·mol-1ChemAxon
Polarizability26.86 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9812
Blood Brain Barrier-0.9659
Caco-2 permeable-0.7112
P-glycoprotein substrateSubstrate0.684
P-glycoprotein inhibitor INon-inhibitor0.8781
P-glycoprotein inhibitor IINon-inhibitor0.9673
Renal organic cation transporterNon-inhibitor0.8974
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7074
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9197
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9287
CYP450 3A4 inhibitorNon-inhibitor0.9343
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8834
Ames testNon AMES toxic0.8409
CarcinogenicityNon-carcinogens0.8863
BiodegradationNot ready biodegradable0.9734
Rat acute toxicity2.5275 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9564
hERG inhibition (predictor II)Non-inhibitor0.9288
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0090000000-afe3df5bdead805eacaf
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-1d8b235dd1e02960dba1
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00dr-0090000000-6fee6c25dfbf9c3a7c13
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-0290000000-0d38029df88ee8018d9a
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00kf-0950000000-9572451e9f596ae94494
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0900000000-05c59c5c9d63de269feb
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-8ef6b84074e243e637bd
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00dr-0090000000-e288fafc6755fa4abcba
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-0290000000-5569e08c145733118852
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0296-0940000000-f3558c829fecc8fea6f0
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0900000000-9b7ad78396782fd2237d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0090000000-19973e6238f364b40ec6
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00dl-0190000000-bec72774da692a955281
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0900000000-9d1b7a0e974ab4c5c2cf
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0090000000-98cef35812448be3e2db
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-006x-0090000000-182d7b602151e8ac7849
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-006t-0950000000-935c99cfc4690ce298f1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-064806e46a30b7dd760b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-6acca58ec4a7b6892bb1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-007k-1900000000-6b18a64209aa89c42af0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00ec-4900000000-70c609482357e411ae42
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-006x-0090000000-127c8a78dd75e131e46a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-006t-0950000000-a3cef97d0495f36363a5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-af9a8ad8ae6e7ade3b9b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-c95568abe549433d67e8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-007k-1900000000-06178e64d95e7221bccb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00ec-4900000000-339502da9d74d89569f0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0090000000-039f3f4bbefe1a1588d8
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-006x-0190000000-99e78b87fa74322fae1d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0900000000-637588735361fe2a9ad0
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-007k-1900000000-b19c47ea3e07181932ab
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-009x-7900000000-6091051edb1a5c40218e
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-002f-9400000000-ff279a7ba0390c8a14df
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00r2-0930000000-00b798f29eb25b7a4565

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzyl alcohols. These are organic compounds containing the phenylmethanol substructure.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzyl alcohols
Direct Parent
Benzyl alcohols
Alternative Parents
Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Primary alcohols / Organopnictogen compounds / Hydrocarbon derivatives / Aromatic alcohols
Substituents
Benzyl alcohol / Phenol / Aralkylamine / 1-hydroxy-2-unsubstituted benzenoid / Secondary alcohol / 1,2-aminoalcohol / Secondary amine / Secondary aliphatic amine / Hydrocarbon derivative / Alcohol
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
phenylethanolamines, phenols, secondary amino compound (CHEBI:2549)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Brichetto L, Milanese M, Song P, Patrone M, Crimi E, Rehder K, Brusasco V: Beclomethasone rapidly ablates allergen-induced beta 2-adrenoceptor pathway dysfunction in human isolated bronchi. Am J Physiol Lung Cell Mol Physiol. 2003 Jan;284(1):L133-9. Epub 2002 Aug 16. [PubMed:12388338]
  2. Chong LK, Suvarna K, Chess-Williams R, Peachell PT: Desensitization of beta2-adrenoceptor-mediated responses by short-acting beta2-adrenoceptor agonists in human lung mast cells. Br J Pharmacol. 2003 Feb;138(3):512-20. [PubMed:12569076]
  3. Yamanishi T, Chapple CR, Yasuda K, Yoshida K, Chess-Williams R: Role of beta-adrenoceptor subtypes in mediating relaxation of the pig bladder trigonal muscle in vitro. Neurourol Urodyn. 2003;22(4):338-42. [PubMed:12808710]
  4. Brouri F, Hanoun N, Mediani O, Saurini F, Hamon M, Vanhoutte PM, Lechat P: Blockade of beta 1- and desensitization of beta 2-adrenoceptors reduce isoprenaline-induced cardiac fibrosis. Eur J Pharmacol. 2004 Feb 6;485(1-3):227-34. [PubMed:14757145]
  5. Choudhry S, Ung N, Avila PC, Ziv E, Nazario S, Casal J, Torres A, Gorman JD, Salari K, Rodriguez-Santana JR, Toscano M, Sylvia JS, Alioto M, Castro RA, Salazar M, Gomez I, Fagan JK, Salas J, Clark S, Lilly C, Matallana H, Selman M, Chapela R, Sheppard D, Weiss ST, Ford JG, Boushey HA, Drazen JM, Rodriguez-Cintron W, Silverman EK, Burchard EG: Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med. 2005 Mar 15;171(6):563-70. Epub 2004 Nov 19. [PubMed:15557128]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Baker JG: The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol. 2005 Feb;144(3):317-22. [PubMed:15655528]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Curator comments
agonist with low affininty
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name
ADRB3
Uniprot ID
P13945
Uniprot Name
Beta-3 adrenergic receptor
Molecular Weight
43518.615 Da
References
  1. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN: Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9. Epub 2004 Jan 17. [PubMed:14730417]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 04:31